Maze Therapeutics (MAZE) Director Paula A. Johnson Receives 36,000-Unit Award

What Happened

• Paula A. Johnson, a director of Maze Therapeutics (MAZE), was granted a derivative award of 36,000 units on 2026-08-13. The award is reported at $0.00 per share (no cash paid at grant) and is recorded as an acquisition of a derivative security, not an open-market purchase or sale.

Key Details

• Transaction date: 2026-08-13; Form 4 filed: 2026-08-17 (filed within the SEC’s two-business-day window).
• Grant: 36,000 derivative units at $0.00 (reported acquisition value $0).
• Vesting: The award vests 1/36th monthly, with the first tranche on 2026-09-13 and each monthly anniversary thereafter, subject to continued service (see footnote).
• Shares owned after the transaction: Not specified in the filing.
• Footnote: Vesting schedule explicitly monthly over 36 months starting Sept 13, 2026.
• Filing timeliness: The Form 4 appears timely (filed within two business days of the reported transaction).

Context

• The award is a time‑based equity grant (reported as a derivative security with $0.00 price), which typically indicates restricted stock units (RSUs) or a similar instrument that convert into common shares as they vest. This is an issuance/compensation event, not a market purchase or sale, and does not by itself indicate insider buying or selling intent.